clinical trial · NCT06932562
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
European Myeloma Network B.V.·phase3·recruiting·n = 1,000
Multiple MyelomaLinvoseltamabDaratumumabLenalidomideDexamethasone
brief summary
This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible). The main purpose of this study is to compare the effect and safety of linvoseltamab with the effect and safety of the standard treatment.
started
Dec 23, 2025
primary completion
Dec 1, 2036
completion
Dec 1, 2036
last updated
Mar 25, 2026
official title
A Randomized, Open-Label, Controlled Phase 3 Study of Comparing Daratumumab, Lenalidomide and Dexamethasone Induction Followed by Linvoseltamab Versus Continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol